JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Kura Oncology Inc

Ouvert

SecteurSoins de santé

10.56 -2.67

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.33

Max

10.85

Chiffres clés

By Trading Economics

Revenu

-8.7M

-66M

Ventes

1.2M

15M

Marge bénéficiaire

-432.509

Employés

192

EBITDA

-8M

-73M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+147.38% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

320M

867M

Ouverture précédente

13.23

Clôture précédente

10.56

Sentiment de l'Actualité

By Acuity

50%

50%

154 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Kura Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 oct. 2025, 23:50 UTC

Actions en Tendance

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct. 2025, 23:25 UTC

Résultats

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct. 2025, 23:18 UTC

Résultats

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct. 2025, 22:20 UTC

Résultats

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct. 2025, 22:13 UTC

Résultats

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct. 2025, 21:38 UTC

Résultats

Correction to Visa Sales Jump Article

28 oct. 2025, 21:17 UTC

Résultats

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct. 2025, 21:07 UTC

Résultats

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct. 2025, 21:02 UTC

Résultats

Mondelez Tempers Outlook as Costs Rise

28 oct. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct. 2025, 23:02 UTC

Résultats

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct. 2025, 23:01 UTC

Résultats

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct. 2025, 22:46 UTC

Résultats

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct. 2025, 22:45 UTC

Résultats

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct. 2025, 22:44 UTC

Résultats

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct. 2025, 22:43 UTC

Résultats

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct. 2025, 22:42 UTC

Résultats

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct. 2025, 22:40 UTC

Résultats

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct. 2025, 22:40 UTC

Résultats

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct. 2025, 22:20 UTC

Résultats

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct. 2025, 22:02 UTC

Résultats

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct. 2025, 21:42 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

28 oct. 2025, 21:42 UTC

Market Talk
Résultats

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct. 2025, 21:20 UTC

Résultats

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct. 2025, 21:19 UTC

Résultats

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct. 2025, 21:18 UTC

Résultats

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparaison

Variation de prix

Kura Oncology Inc prévision

Objectif de Prix

By TipRanks

147.38% hausse

Prévisions sur 12 Mois

Moyen 26 USD  147.38%

Haut 40 USD

Bas 11 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

11

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

5.575 / 6.6Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

154 / 373Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat